Immunovant, Inc. (NASDAQ:IMVT) Insider Julia G. Butchko Sells 10,115 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVT) insider Julia G. Butchko sold 10,115 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $29.06, for a total transaction of $293,941.90. Following the transaction, the insider now owns 451,627 shares in the company, valued at approximately $13,124,280.62. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Immunovant Price Performance

Immunovant stock opened at $28.22 on Friday. The firm has a 50 day moving average of $33.00 and a 200 day moving average of $36.05. Immunovant, Inc. has a 12-month low of $15.08 and a 12-month high of $45.58.

Immunovant (NASDAQ:IMVT) last released its earnings results on Monday, February 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. Sell-side analysts predict that Immunovant, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Immunovant

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Immunovant by 47.5% in the 3rd quarter. FMR LLC now owns 7,748,546 shares of the company’s stock worth $297,467,000 after acquiring an additional 2,494,678 shares in the last quarter. Vanguard Group Inc. grew its holdings in Immunovant by 14.0% during the 3rd quarter. Vanguard Group Inc. now owns 6,233,146 shares of the company’s stock valued at $239,290,000 after buying an additional 764,530 shares in the last quarter. BlackRock Inc. grew its holdings in Immunovant by 6.7% during the 2nd quarter. BlackRock Inc. now owns 4,201,314 shares of the company’s stock valued at $79,699,000 after buying an additional 264,133 shares in the last quarter. State Street Corp grew its holdings in Immunovant by 27.5% during the 1st quarter. State Street Corp now owns 3,967,605 shares of the company’s stock valued at $61,538,000 after buying an additional 854,662 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Immunovant during the 4th quarter valued at approximately $112,356,000. 47.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on IMVT. Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a research note on Friday, January 12th. JPMorgan Chase & Co. began coverage on shares of Immunovant in a research note on Tuesday, February 20th. They set an “overweight” rating and a $51.00 target price on the stock. Oppenheimer began coverage on shares of Immunovant in a research note on Thursday, March 28th. They set an “outperform” rating and a $50.00 target price on the stock. Truist Financial restated a “buy” rating and set a $48.00 target price on shares of Immunovant in a research note on Monday, March 25th. Finally, Wolfe Research assumed coverage on shares of Immunovant in a research note on Thursday, February 15th. They set an “outperform” rating and a $55.00 target price on the stock. Seventeen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $48.00.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.